Predicting early treatment response in advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a predictive model for early response evaluation in patients with advanced hepatocellular carcinoma receiving atezolizumab-bevacizumab combination therapy. The study will compare treatment responses of this combination therapy against atezolizumab alone and bevacizumab alone. By identifying early indicators of treatment efficacy, the study seeks to improve patient management and outcomes. Participants will be monitored for their response to the therapy as part of the evaluation process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy
* Patients willing to participate in this study

Exclusion Criteria:

* Individuals with a history of severe contrast allergy
* Individuals with severe comorbidities (according to the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction.)

Where it's running

• Seoul National University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Jeong-Hoon Lee, MD PhD
• Email: pindra@empal.com
• Phone: +82-2-2072-2228

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Carbon ion radiotherapy plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This trial will try adding carbon ion radiotherapy to standard atezolizumab‑bevacizumab treatment for adults with advanced hepatocellular carcinoma to see if it controls tumors better and improves survival.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07246668

• Combining atezolizumab and bevacizumab with Y-90 radioembolization to help people with liver cancer get to transplant

  This trial tests whether adding immunotherapy (atezolizumab plus bevacizumab) to Y-90 radioembolization can help people with hepatocellular carcinoma bridge to or be downstaged for liver transplant.

  Recruiting Phase 4 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07059494

• Preventive endoscopic banding for high-risk esophageal varices in people with hepatocellular carcinoma starting atezolizumab plus bevacizumab

  This study will test whether doing preventive endoscopic banding of high-risk esophageal varices can reduce bleeding in people with hepatocellular carcinoma who are starting atezolizumab plus bevacizumab.

  Recruiting Phase 2 Asan Medical Center · Seoul, Song-pa · NCT06819566

• Combination therapy for hepatocellular carcinoma using atezolizumab, bevacizumab, and memantine

  This study is testing a new combination of three medications to see if it can help people with advanced liver cancer feel better and improve their quality of life.

  Recruiting at 2 sites Phase 2 Inova Health Care Services · Fairfax, Virginia and 1 other locations · NCT06789757

• Combining Atezolizumab and Bevacizumab with Photon Radiotherapy for Liver Cancer

  This study is testing if combining two cancer drugs, atezolizumab and bevacizumab, with radiation therapy can help people with liver cancer that can't be surgically removed live longer and feel better.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06339424

• Valemetostat with atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This will test whether adding the oral drug valemetostat to atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting Phase 1/2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06294548

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.